Company Profiles

Find premium company profile research reports. Purchase and download high quality report analysis, company reports, and much more

DocStore Search:
Per Page: 152550
  • Roche Diagnostics Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    Roche Diagnostics Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    Roche Diagnostics Corporation is a provider of diagnostic tests and systems. It develops innovative products and services that address the prevention, diagnosis and treatment of diseases. Roche Diagnostics Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companie
    View Document
  • Commonwealth Scientific and Industrial Research Organisation - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    Commonwealth Scientific and Industrial Research Organisation - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    Commonwealth Scientific and Industrial Research Organisation (CSIRO) is Australia's national science agency. The company’s research areas include climate adaptation, biosecurity, energy transformation, food futures, and digital productivity and services among others. Their research departments are animal, food and health sciences, astronomy and space science, earth science and resource engineering, energy technology, ecosystem sciences, marine and atmospheric research, materials science and engineering. The company provides resources and science programs for special events and schools around Australia. It also organizes seminars and workshops to family and school events. The Company’s site at CSIRO Montpellier, France concentrates on precautionary biosecurity research and biological control. It has processing units in Australian Capital Territory, New South Wales locations, South Australian, Northern Territory, Western Australian, Victoria, Queensland and Tasmania. CSIRO is headquartered in Canberra, Australian Capital Territory, Australia. Commonwealth Scientific and Industrial Research Organisation - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Ye
    View Document
  • Ingenuity Systems, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    Ingenuity Systems, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    Ingenuity Systems, Inc. (Ingenuity) is a healthcare information technology company. The company provides information solutions and services for life science researchers. It offers biomedical information and analysis solutions for the exploration, interpretation and analysis of complex biological systems. Ingenuity’s products include IPA, ireport, variant analysis and custom solutions. The company provides complete solutions for researchers and clinicians at pharmaceutical, biotechnology, academic, diagnostic and clinical institutions worldwide to better understand the complex systems foundation to human health and disease. Its investors include ACCEL PARTNERS, INDUSTRY ventures, QuestMark Partners, rho and Three Arch partners. Ingenuity is headquartered in Redwood, California, the US. Ingenuity Systems, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acqui
    View Document
  • TransGenic Inc. (2342) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    TransGenic Inc. (2342) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    TransGenic Inc. (TransGenic) is a biotechnology company with focus on the development and distribution of genetically engineered animals and antibodies. It operates in three types of business, namely, Genomics business, CRO business and Antibody and Reagent business. TransGenic conducts business centering on two fundamental technologies, namely, the knockout mouse-producing technology and the antibody-producing technology. It also discovers and identifies innovative druggable targets. The products and services offered by the company include knockout mouse and phenotype database, custom production of knockout mice and other mouse related products, such as model mice and frozen embryo. Its patented GANP (Germinal Center Associated Nuclear Protein) technology is used as a fundamental technology in its antibody-related technological platforms. TransGenic is headquartered in Kumamoto, Japan. The company supports life science researches through collaborations with research institutes in universities and pharmaceutical companies, by producing knockout mice and offering gentic information to other research institutes. TransGenic Inc. (2342) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financ
    View Document
  • Transcend Services, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    Transcend Services, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    Transcend Services, Inc., (Transcend) is the second largest provider of clinical documentation solutions for healthcare organizations in the US. It offers a range of integrated clinical documentation solutions through its BeyondTXT enterprise system. The company specializes in providing medical transcription services through two primary service delivery options including, Customer Platform and its own platforms such as BeyondTXT Platform. The company's transcription services include three primary phases such as, phase I: dictation capture, phase II: voice to text, and phase III: distribution. Furthermore, based on revenue. The company caters its services to more than 250 clients nationwide. Transcend is headquartered at Atlanta in Georgia, the US. The company intends to partner with healthcare providers to deliver high value to the customers. And as a part of its growth strategy, it acquires closely related sizable medical transcription companies. Transcend Services, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a f
    View Document
  • Luminex Corporation (LMNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    Luminex Corporation (LMNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    Luminex Corporation (Luminex) is a medical devices company, which develops, manufactures and markets its proprietary biological testing technologies. Its proprietary technologies consist of xMAP technology, xTAG and MultiCode technology. It operates its business through two reportable business segments, namely, the Technology and Strategic Partnerships (TSP) segment and the Assays and Related Products (ARP) segment. Its TRP segment's product portfolio consists of Luminex LX 100/200, FLEXMAP 3D and MAGPIX; xPONENT, MicroPlex Microspheres, MagPlex Microspheres, xTAG Microspheres, SeroMAP Microspheres, and calibration and control microspheres. The ARP segment comprises assay products including respiratory viral family, gastrointestinal pathogen detection family, MultiCode assays and products family, among others. Luminex offers its product and services in the North America, Europe and Asia-Pacific. Luminex is headquartered in Texas, the US. The company focuses on strengthening its alliances with its partners, as recently, it entered into a collaboration and license agreement with Merck for the development of a companion diagnostic device. Luminex Corporation (LMNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offer
    View Document
  • Biosensors International Group, Ltd. (B20) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    Biosensors International Group, Ltd. (B20) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    Biosensors International Group, Ltd. (Biosensors) is a medical devices company. It undertakes the developing, manufacturing and marketing of medical devices utilized in interventional cardiology and critical care procedures. The company develops drug-eluting stents (DES) and a pipeline of next-generation products set to gain market share from traditional therapies such as conventional drug eluting stents, bare-metal stent and balloon dilatation catheters. It also focuses on the technology addressing a DES system including the stent, delivery catheter, polymer and proprietary drug. Geographically, the company operates through its subsidiaries in Singapore, Switzerland, China, US, Japan, Indonesia, India, France, Germany and Netherlands. Biosensors is headquartered in Singapore. The company focuses on the expansion of its product portfolio, as recently it acquired all assets of Spectrum Dynamics, a leading company in advanced functional assessment technologies. Biosensors International Group, Ltd. (B20) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported b
    View Document
  • Henderson Morley Plc (HML) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    Henderson Morley Plc (HML) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    Henderson Morley Plc (Henderson Morley) is a biotechnology company engaged in the development of anti-viral drugs and vaccines and biological products for a wide range of diseases in humans and animals. It develops in-house discoveries up to a stage which could be licensed to pharmaceutical or development partners. It develops anti-viral platform technology, animal healthcare products and vaccines. It has developed a broad pipeline of clinical and pre-clinical candidates in a wide range of disease areas. Its in-house anti-viral technology known as Ionic Contraviral Therapy (ICVT), effective against a broad range of viruses, including HPV (responsible for skin and genital warts) (adenovirus cause of viral red-eye), herpes simplex (cold sores and genital herpes) and some orphan disease indications. The company is headquartered in Birmingham, the UK. In January 2009, the company entered into a collaborative research agreement with Colorado State University to explore PREPS and L-particles as a treatment for dog cancers. Also, in January 2009, Henderson entered into a co-development agreement with UK Glass Eels Ltd to produce a vaccine against Eel Herpes. Henderson Morley Plc (HML) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/D
    View Document
  • Aradigm Corporation (ARDM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    Aradigm Corporation (ARDM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    Aradigm Corporation (Aradigm) is a specialty pharmaceutical company. It carries out the development and commercialization of inhalation drugs for the prevention and treatment of severe respiratory diseases. The company's product portfolio focus on treating cystic fibrosis, bronchiectasis, inhalation tularemia, anthrax infections, and preventing respiratory and other diseases in tobacco smokers through smoking cessation. Its proprietary pulmonary drug delivery platform, AERx, can be customized for the delivery of drugs to the target along with liposomal formulations. Its research and development program includes the development of liposomal ciprofloxacin to treat inhalation anthrax under a technology demonstration program funded by the Defence Research and Development Canada (DRDC) as part of their interest in developing products to counter bioterrorism. Aradigm is headquartered in Hayward, California, the US. The company strategically focuses on entering into co-promotion, co-development and other marketing arrangements with collaborators to reduce costs and increase revenues through royalties, license fees and milestone payments. Aradigm Corporation (ARDM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Priva
    View Document
  • Epistem Holdings Plc (EHP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    Epistem Holdings Plc (EHP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    Epistem Holdings Plc (Epistem) is a biopharmaceutical and biotechnology company providing contract research facilities and services to others pharmaceuticals companies. It also undertakes the development of novel therapeutics used in oncology and wound healing. It operates through three reportable segments, namely, Contract Research Services, Novel Therapies and Personalised Medicine. It provides molecular biomarkers to measure drug induced gene expression from individual plucked hairs. It specializes in the marketing of epithelial stem cells in the areas of oncology, gastrointestinal diseases and dermatological applications. It offers reliable, innovative research models to the pharmaceutical, biotechnology and healthcare industries. Its principal subsidiaries include Epistem Limited and Epistem Inc. Epistem headquartered in Manchester, the UK. Epistem focuses on its research and development activities with emphasis on identifying new drug therapies to address major diseases of oncology, gastrointestinal disease, dermatology and aging. To this end, the company entered into agreement and collaboration with various pharmaceutical companies such as Becton Dickinson, GlaxoSmithKline and so on. Epistem Holdings Plc (EHP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals
    View Document
  • Proteome Sciences Plc (PRM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    Proteome Sciences Plc (PRM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    Proteome Sciences Plc (Proteome Sciences) is a protein biomarker company. The company delivers content for personalized medicine in different areas such as biomarker assays, biomarker services, isobaric and isotopic reagents and proprietary biomarkers. It specializes in providing proteomics and peptidomics services and applications, and mass spectrometry protein analysis capability. The company’s offerings cover various diseases such as neurodegenerative diseases, stroke and cancer. It also discovered and patented blood biomarkers, such as Alzheimer’s disease, brain damage, stroke and lung cancer for diagnostic and treatment applications. Proteome Sciences is headquartered in Cobham, the UK. The company focuses to develop advanced methods in its operational markets. In line with this, recently, the company signed a technology agreement with Thermo Fisher Scientific. Proteome Sciences Plc (PRM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information includi
    View Document
  • Syneron Medical Ltd. (ELOS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    Syneron Medical Ltd. (ELOS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    Syneron Medical Ltd. (Syneron Medical) is a medical device company providing aesthetic treatments. It designs, develops and markets aesthetic medical products based on the electro-optical synergy (ELOS) technology that utilizes the synergy between electrical energy and optical energy. Its products target a range of non-invasive aesthetic medical procedures. Syneron Medical focuses on wrinkle reduction, hair removal, and rejuvenation of the skin’s appearance by the treatment of superficial benign vascular and pigmented lesions, treatment of leg veins, acne treatment, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and a minimally invasive product for laser-assisted lipolysis. The company directly sells its products across North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and indirectly through distributors in more than 90 countries. Syneron Medical is headquartered in Yokneam Illit, Israel. The company focuses on thoughtfully designed innovations, based on extensive consumer insight, to meet the needs of aesthetic clinics and professionals. Syneron envisages establishing its position through the development of innovative products and services and enhancement of existing ones, internal development, strong partner relationships, strategic collaborations and acquisitions. Syneron Medical Ltd. (ELOS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalDat
    View Document
  • Arizona State University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    Arizona State University - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    Arizona State University is one of the premier metropolitan research university.It is headquartered in Arizona, the US. Arizona State University - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief de
    View Document
  • ZyGEM Corporation Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    ZyGEM Corporation Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    ZyGEM Corporation Ltd (ZyGEM) is a biotechnology company. The company develops enzymatic tools for the extraction of DNA. Its products include prepGEM, forensicGEM, livestockGEM and RNAGEM. ZyGEM offers molecular biology enzymes, diagnostics, DNA extraction and detection products and individual enzymes. Its enzymes are used in molecular biology, diagnostics and industrial applications. The company’s products also find application in the field of research, forensics, molecular diagnostics applications, environmental sustainability and agriculture. It markets products through brand such as PrepGEM, ForensicGEM, LivestockGEM and RNAGEM. The company markets products through distributors in the areas of Australia, Singapore, South Africa, Malaysia, Indonesia, Europe, among others. ZyGEM is headquartered in Hamilton, New Zealand. ZyGEM Corporation Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the com
    View Document
  • TARIS BioMedical, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    TARIS BioMedical, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    TARIS Biomedical, Inc. (TARIS) is a pharmaceutical company. The company develops drugs and therapeutics for bladder disorders. Its products under clinical development include LiRIS, TD6989, TD3633, TD1770, TD9594 and TD4001. TARIS offers products for the treatment of interstitial cystitis, ureteral stent symptoms, all-risk NMIBC, BCG failing NMIBC, muscle invasive disease, overactive bladder and neurogenic bladder. The company’s drug delivery system combines three procedures such as osmotic delivery, shape memory technology and implant retention. Its product, LiRIS is used to deliver lidocaine directly into the bladder to relieve symptoms associated with interstitial cystitis. TARIS is headquartered in Lexington, Massachusetts, the US. TARIS BioMedical, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Regi
    View Document
Per Page: 152550